Effect of slow-acting antirheumatic drugs on lipid profile in patients with rheumatoid arthritis
10.3760/cma.j.issn.0254-9026.2009.11.004
- VernacularTitle:慢作用抗风湿药对类风湿关节炎患者血脂的影响
- Author:
Hua XU
;
Yingyuan CHEN
- Publication Type:Journal Article
- Keywords:
Arthritis;
rheumatoid;
Dyslipidemias
- From:
Chinese Journal of Geriatrics
2009;28(11):890-892
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of slow-acting antirheumatic drugs on lipid profile and disease activity index in patients with rheumatoid arthritis (RA). Methods Eighty-two patients with RA who met the American College of Rheumatology (ACR) criteria were treated with disease-modifying antirheumatic drugs including methopterin (MTX), salazosulfapyridine (SASP) and hydroxychloroquine sulfate, while seventy-nine healthy volunteers were used for control. All persons were followed up for 12 months. The observations included 28 joint indices score (DAS-28), lipid profile, c-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). Results Compared with the control group before treatment, RA patients exhibited higher serum levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and triglycerides. Whereas, high-density lipoprotein cholesterol (HDL-C) was significantly lower. After 12 months treatment, the disease activity index[(6.7±0.6)vs. (2.1±0.9)], ESR [(62±18)mm/h vs. (13±9)mm/h] and CRP [(2.2±0.3 ) mg/L vs. (0. 3±0.2 ) mg/L, all P<0.01] were significantly decreased and HDL-C [1.0±0. 1)mmol/L vs. (1.5±0. 3)mmol/L, P<0. 01] was increased in RA patients. Conclusions RA patients are characterized by an atherogenic lipid profile, which are improved after therapy. Immuno-intervention to control disease activity may reduce the risks for the atherosclerotic process and cardiovascular events in RA patients.
